Last reviewed · How we verify
Clotrimazole 1%
Clotrimazole inhibits fungal cell membrane synthesis by blocking the conversion of lanosterol to ergosterol via inhibition of fungal cytochrome P450 enzymes.
Clotrimazole inhibits fungal cell membrane synthesis by blocking the conversion of lanosterol to ergosterol via inhibition of fungal cytochrome P450 enzymes. Used for Topical fungal infections (dermatophytes, Candida, Malassezia), Vaginal candidiasis, Oropharyngeal candidiasis.
At a glance
| Generic name | Clotrimazole 1% |
|---|---|
| Sponsor | Jinnah Postgraduate Medical Centre |
| Drug class | Imidazole antifungal |
| Target | Fungal cytochrome P450 (lanosterol 14α-demethylase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clotrimazole is an imidazole antifungal that disrupts the synthesis of ergosterol, a critical component of fungal cell membranes. By inhibiting the fungal enzyme lanosterol 14α-demethylase (a cytochrome P450 enzyme), it causes accumulation of toxic sterol precursors and membrane instability, leading to fungal cell death. This mechanism is selective for fungal cells over human cells due to structural differences in sterol synthesis pathways.
Approved indications
- Topical fungal infections (dermatophytes, Candida, Malassezia)
- Vaginal candidiasis
- Oropharyngeal candidiasis
Common side effects
- Local irritation, burning, or stinging at application site
- Erythema or pruritus
- Allergic contact dermatitis
Key clinical trials
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (PHASE1, PHASE2)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract (EARLY_PHASE1)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor (PHASE1, PHASE2)
- Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas (EARLY_PHASE1)
- Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clotrimazole 1% CI brief — competitive landscape report
- Clotrimazole 1% updates RSS · CI watch RSS
- Jinnah Postgraduate Medical Centre portfolio CI